Therapeutic monoclonal antibodies (mAbs) exert antitumor activity through various mechanisms including apoptotic signalization, complement dependent cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) or phagocytosis (ADCP). G-CSF and GM-CSF have been reported to increase the activity of antibodies in preclinical models and in clinical trials. In order to determine the potential role of pegfilgrastim as an enhancer of anticancer antibodies we performed a comparative study of filgrastim and pegfilgrastim. We found that pegfilgrastim was significantly more potent than filgrastim in murine xenograft models treated with mAbs. This was observed with rituximab in CD20+ models and with trastuzumab in HER2+ models. Stimulation with pegfilgrastim was associated with significant enhancement of leukocyte content in spleen as well as mobilization of activated monocytes/granulocytes from the spleen to the tumor bed. These results suggest that pegfilgrastim could constitute a potent adjuvant for immunotherapy with mAbs possessing ADCC/ADCP properties.
Introduction
Monoclonal antibodies (mAbs) are increasingly used for the treatment of cancer patients. Their mechanisms of action are complex since antibodies can either target the tumor cells themselves or the microenvironment, including tumor vasculature or the surrounding immune cells. Among antibodies targeting tumor cells directly, various mechanisms of action are likely to be involved including direct apoptotic signalization after recognition of the cognate antigen and extracellular effector mechanisms such as complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) or its closely related phenomenon antibody-dependent cellular phagocytosis (ADCP) (1) . Despite this diversity of mechanisms of antitumor activity, treatment by mAbs has not allowed to obtain cure in most of the approved indications, either as a single agent or in combination with other agents. The case of follicular non-Hodgkin's lymphoma (NHL) is exemplary since certain patients can benefit from single agent therapy but resistance to treatment will eventually develop. In addition, a significant proportion of responding patients will no longer benefit of retreatment with this monoclonal antibody after relapse (2) .
Most clinically used mAbs belong to the IgG subclass and their Fc domain interacts with IgG
Fc receptors (Fc receptors). The human IgG receptor family includes several members, most of which are activating (CD64 or Fc RI, CD32a or Fc RIIa, CD16a or Fc RIIIa, CD16b or Fc RIIIb) and one which is inhibitory (CD32b or Fc RIIb) with various affinities for the IgG subclasses. Several of the mAbs currently used in the clinic rely at least partly on Fc receptor-mediated mechanisms and novel antibodies, such as obinutuzumab have been specifically engineered to possess enhanced ADCC properties (3) . Fc receptor polymorphisms that affect affinity for IgG (Fc RIIa-131H/R and Fc RIIIa-158V/F) have been found to influence the clinical response to rituximab (anti-CD20) (4), cetuximab (anti-EGFR) 5 or trastuzumab (anti-HER2; human epidermal growth factor receptor 2) (5) therapy in lymphoma, colorectal and breast cancer patients, respectively, suggesting that Fc receptor-mediated effector functions play an important role in cancer treatment. The nature of the Fc receptor-bearing cells involved in cytotoxic activity is not completely elucidated. Classically, Natural Killer (NK) cells have been considered as the main effector cells for ADCC (6) . NK cells express the high affinity receptorFc RIIIa, and the association between Fc receptor alleles and clinical success of mAb therapy has been attributed to NK cells (7) . However, other cell populations can act as potential effector cells for mAbmediated tumor regression, including myeloid effector cells such as monocytes/macrophages and neutrophils (8) .
Neutrophils are the most abundant circulating leukocyte subpopulation in peripheral blood.
In addition, this population can be amplified and/or mobilized by the administration of granulocyte (macrophage)-colony stimulating factors (G-CSF and GM-CSF) (9 11).
Neutrophils have been described as potent cytotoxic effectors, able to produce many cytotoxic molecules (12) and exert direct tumoricidal activity (13) . Their ability to directly recognize tumor cells is limited but is highly enhanced in the presence of mAbs (14) .
Fc receptors expressed on neutrophils are Fc RIIa, Fc RIIIb, and Fc RI. Fc RIIIb is the most abundant Fc receptor on neutrophils, but evidence suggests that it is not involved in efficient tumor cell cytotoxicity (15) . Antibody-dependent killing of tumor cells by neutrophils in the absence of G-CSF is described to be non-existent or weak (16, 17) and is likely mediated through Fc RIIa (18). Therefore, specific targeting of Fc RI has been proposed, as this may overcome potential inhibitory signals through Fc RIIb when IgG mAb are employed (19) .
In order to improve antibody dependent cytotoxicity of leukocytes, co-administration of monoclonal antibodies and different cytokines has been performed, in particular with GM-CSF and G-CSF. Cartron et al (20) performed a phase II clinical study combining GM-CSF and rituximab in patients with relapsed follicular lymphoma. This study reported an improvement in the expected complete response rate with the combination compared to monotherapy (39% vs 6%, respectively) (21) . The authors explain this result by the recruitment and activation of granulocytes and monocytes, leading to an increased antitumor potential, involving both ADCC and ADCP (22 (24) . Van der Kolk et al showed in a phase I/II clinical trial that, when G-CSF was combined with rituximab in CLL, the median time to progression observed for the combination was 24 months, and only 13 months for rituximab as a single agent although the overall response rate was comparable in both groups (25) .
Recombinant G-CSF (filgrastim) used to treat patients has a short half-life of in the blood stream (3-4 hours). Pegfilgrastim, a filgrastim analog carrying a 20kDa polyethylene glycol molecule on its N-terminus has a half-life of 15 to 80 hours in blood. Pegylation increases the molecular weight of filgrastim above the threshold for renal clearance. Consequently, the drug is believed to be mostly cleared by neutrophils. Neutrophil-mediated clearance takes longer than renal clearance, thereby increasing the half-life of the drug. We show that respectively. Using MycoAlertKit (Lonza, base, Switzerland) all cell lines used in this study were tested mycoplasma-negative.
Cell assays
NFS-60, a murine myeloid leukemia cell line which proliferates in response to G-CSF, was used for cell cycle experiments (27) . Cells were starved for 18 hours (no Il3 nor G-CSF) in order to block NFS60 cells in G0/G1 phase, then various concentrations of filgastrim or pegfilgastrim (from 5pmol/L to 1nmol/L) were added to the cells for 18 hours. Cell cycle distribution was estimated by flow cytometry using propidium iodide as previously described (28) .
Neutrophil preparation
Blood samples from healthy donors were provided by the Lyon Blood Bank. Neutrophils were obtained by performing a density gradient centrifugation (Pancol, Pan-Biotech) followed by a dextran separation (3% Dextran, Sigma Aldrich). Remaining red blood cells were removed using a lysis solution (BD Pharm Lyse, BD Bioscience) and purity of neutrophils was evaluated by flow cytometry using CD45/SSC gating.
Leukocyte subpopulations in mice
The phenotype of leukocyte subpopulations in the blood, spleen, bone marrow, and tumor were studied after four injections with rituximab combined or not with filgrastim or pegfilgrastim. Briefly, spleen and tumor were cut in small pieces and incubated in PBS containing 0.5% FCS and 1mg/ml collagenase A (Roche Diagnostics GmbH, Mannheim, Germany), 0.1mg/ml hyaluronidase and 10μg/ml DNase (Sigma, Saint Quentin Fallavier, 
Human leukocytes
Leukocyte populations of healthy donors used for in vitro experiments were assessed by flow cytometry using anti-CD13 VioBlue (clone BW264/56), anti-CD16 (VEP13), anti-CD14 APC-Vio770 (clone TUK4) anti-CD45 APC-vio700 (clone 5B1), anti-CD19 Pe-Vio770 (LT19), anti-CD15 APC (clone VIMC6) and anti-CD56 PE (AF12-7H3) obtained from Miltenyi Biotec.
Human granulocyte studies
Effect of G-CSF formulations on the phagocytic activity of normal human leukocytes was assessed with two different assays. Phagotest (Glycotope Biotechnology), which measures the ingestion of one or more labeled and opsonized bacteria, E.coli-FITC per cell, was used to determine the phagocytic properties of granulocytes, lymphocytes and monocytes.
FagoFlowEx Kit (Exbio Diagnostics) was used to measure the respiratory (oxidative) burst after their stimulation with E. coli bacteria in human heparinized whole blood using flow cytometry.
Antibody-dependent cellular phagocytosis (ADCP) assay
Antibody dependent cellular phagocytosis mediated by neutrophils was evaluated by fluorescence transfer of target cells to effector cells. The assay was adapted from
McEarchern et al (29) . Tumor cells were labeled with PKH26, a fluorescent cell membrane dye, according to the manufacturer's instructions (Sigma, St Louis, MO). Neutrophils stimulated or not with filgrastim or pegfilgrastim (at a concentration of 10ng/ml during 2 hours at 37°C) were used as effector cells. Effectors and target cells were co-incubated at an E:T ratio of 2:1 overnight at 37°C 5% CO2, in the presence or absence of monoclonal antibodies. After incubation, cells were washed once in PBS 2% FCS stained with 3μl of anti-CD15-APC (clone HI98, BD Bioscience) for 30 minutes at 4°C and analyzed by flow cytometry.
In vivo experiments
Six-week-old female CB17 severe combined immunodeficient (SCID) mice purchased from Charles River Laboratories (L'Arbresle, France) were bred under pathogen-free conditions at the animal facility of our institute. Animals were treated in accordance with the European Treatments were administered once a week: monoclonal antibodies were injected intraperitoneally and G-CSF formulations intravenously on the same day.
To define optimal doses of filgrastim and pegfilgrastim for tumor growth inhibition experiments, a dose-response experiment was performed using various quantities of filgrastim and pegfilgrastim (3μg to 60μg per injection per mouse) combined with rituximab.
Optimal doses were then used for in vivo experiments to evaluate their effect when coinjected with different doses of monoclonal antibody (data not shown).
Statistical analysis
In vitro data were analyzed using Student's t test. For tumor growth inhibition assays, one way ANOVA was used to compare treatment groups. Analyses were performed with Statistica 8.0 (StatSoft, Inc.). 
Results

Effect of filgrastim and pegfilgrastim on the antitumor activity of therapeutic mAbs in vivo
The efficacy of the combination of pegfilgrastim, filgrastim and therapeutic antibodies was In the MDA-MB361 model, with three mice per group (Fig. 1B) , TGI values were 17, 94 and 112% for pegfilgrastim alone, trastuzumab alone and pegfilgrastim/trastuzumab, respectively. In addition to significant differences between the treatment groups, a complete tumor remission was observed in the pegfilgrastim/trastuzumab group but not in the other groups. Similar observations were obtained with a third model (A549 cell line, Supplementary Fig. S1 ). Furthermore, in the RL model, an increased mice survival was observed in the pegfilgrastim/rituximab treated group (Supplementary Fig. S2 ).
Effect of filgrastim and pegfilgrastim on cell cycle distribution of NFS60 cells
Cell cycle experiments comparing variable concentrations of filgrastim and pegfilgrastim showed that both molecules induce cell cycle entry of starved NFS60 cells, with a decrease in the percentage of cells in G0/G1 and a corresponding increase of the cells in G2/M phase. In this assay filgrastim was more potent than pegfilgrastim over the range of concentrations tested (0.1-2 ng/ml) with no dose-response effect for either molecule. Similar results were observed at concentrations of 5 ng/ml or greater ( Fig. 2A and B) .
Effect of filgrastim and pegfilgrastim on phagocytic activity of normal human neutrophils
Phagocytic activity of normal human neutrophils was explored in samples obtained from three healthy donors (Fig. 3A) . Filgrastim induced a significant increase of the percentage of neutrophils performing phagocytosis in two out of three healthy donors (** p<0,005), whereas pegfilgrastim induced a significant increase of the percentage of neutrophils performing phagocytosis in three out of three healthy donors (* p<0,05). However no significant difference could be measured between samples stimulated with filgrastim or pegfilgrastim. Evaluation of ROS production by neutrophils using Fagoflow showed similar results. As shown in Fig. 3B , filgrastim and pegfilgrastim induced a significant increase of the percentage of neutrophils producing ROS (* p<0,05) while no significant difference of ROS production could be measured between leukocytes stimulated with filgrastim or pegfilgrastim. These two functional assays confirmed the ability of filgrastim and pegfilgrastim to enhance phagocytic and ROS-producing properties of neutrophils, with no significant difference observed between the two molecules.
Effect of filgrastim and pegfilgrastim on ADCP properties of normal human neutrophils
Phagocytosis of target cells was measured by incorporation of the fluorescent lipophilic molecule PKH67 used to label target cells into neutrophils. While trogocytosis may occur, this assay is commonly used to evaluate antibody dependent cellular phagocytosis in vitro (31) . As presented in Fig. 3C , the presence of monoclonal antibody induced a significant increase of phagocytosis of tumor cells by neutrophils. In addition, pre-incubation of neutrophils with filgrastim and pegfilgrastim significantly enhanced their capacity to perform phagocytosis. Moreover in 2 out of 3 donors, pegfilgrastim was more potent than filgrastim in inducing an increased phagocytosis by neutrophils (* p<0,05). 
Effect of filgrastim and pegfilgrastim on leukocyte populations in vivo
Mice received repeated injections of rituximab combined or not with filgrastim or pegfilgrastim (n=5 mice per group). The cellularity of spleens was found to strikingly increase in mice treated with pegfilgrastim without rituximab in comparison to controls; with cell numbers increased five-to six-fold (Fig. 4A) . There was also a significant increase of spleen size of mice treated with pegfilgrastim (with or without rituximab) compared to the other groups (p<0.05) (Fig. 4B and C) . The ratio of spleen leukocyte subpopulations was also analyzed. For each subpopulation assessed, association of pegfigrastim and rituximab induced an increase in the number of cells when compared to rituximab alone. The activated monocyte population was multiplied 19-fold and the granulocyte population 18-fold ( Supplementary Fig. S3 ).
We analyzed leukocyte subpopulations to identify those which were preferentially increased. As shown in Fig. 5A granulocytes, was increased in the spleen of mice treated with filgrastim and pegfilgrastim compared to both untreated and rituximab-treated mice, but no significant difference was observed between filgrastim and pegfilgrastim treatment groups.
We also assessed absolute number of leukocyte subpopulations within the spleen (Fig. 5B ).
In parallel with the weight increase observed with pegfilgrastim treatment (with or without rituximab), a systematic and significant increase of the number of cells of all leukocyte subpopulations was observed (p<0.05). In blood (Fig. 5C ), significant differences were only observed for the pegfilgrastim groups (with or without rituximab) with a significant increase of the Ly6G + Ly6C low population and a significant decrease of the monocytic populations 
Discussion
Our results show that pegfilgrastim enhances the antitumor activity of ADCC/ADCPperforming antibodies such as rituximab and trastuzumab in preclinical models and that this effect was greater than that observed with filgrastim. This immuno-adjuvant effect was associated with the amplification and recruitment of neutrophils, including in the tumor site.
Clinical studies, such as the one currently being conducted combining rituximab and pegfilgrastim in patients with NHL (NCT01682044) should determine whether this combination is beneficial in the clinic. Possible differences between filgrastim and pegfilgrastim may be the kinetic of stimulation of accessory cells, which is expected to be more prolonged in the case of pegfilgrastim or enhanced uptake of pegfilgrastim by accessory cells. Some investigators have used G-CSF or GM-CSF in an attempt to enhance Mab potency in preclinical models and patients. Hernandez-Ilizaliturri combined murine G-or GM-CSF with rituximab in a murine xenograft model in SCID mice and found that these molecules significantly increased the antitumor effect of the antibody in this setting (37) . These authors also showed that neutrophil depletion in a murine model was associated with a loss of antitumor activity of rituximab (38) . Van der Kolk administered G-CSF 5 μg/kg/day for 3 days with rituximab infusion on day 2 in 26 patients with relapsing low-grade lymphoma (25) .
Tolerance was satisfactory and time to progression was considered to be unexpectedly long in some patients. Cartron In conclusion pegfilgrastim appears to be an attractive candidate to potentiate the antitumor activity of monoclonal antibodies with ADCC or ADCP properties such as rituximab and trastuzumab. Further studies are required to determine whether these observations can be generalized to other target antigens and other monoclonal antibodies.
Supplementary information is available at Molecular Cancer Therapeutic's website. A, effect of filgrastim and pegfilgrastim on spleen cellularity. Spleens were obtained two days after the last treatment from five mice which were either not treated or treated weekly with rituximab (30mg/kg), filgrastim (375 mg/kg) with or without rituximab (30mg/kg) and pegfilgrastim (750mg/kg) with or without rituximab (30mg/kg), during 4 weeks. Spleen were dissociated into single-cell suspensions and leukocytes counted by trypan blue exclusion.
Results are the mean ± SEM of five mice per group (*, p<0,005). B, effect of filgrastim and pegfilgrastim on spleen size and leukocyte subpopulations. Spleens were obtained two days after the last treatment from five mice which were either not treated or treated weekly with rituximab (30mg/kg), filgrastim (375 mg/kg) with or without rituximab (30mg/kg) and pegfilgrastim (750mg/kg) with or without rituximab (30mg/kg), during 4 weeks. Spleen size was not increased in mice exposed to filgrastim + rituximab in comparison to mice exposed to rituximab alone but was significantly increased in mice exposed to pegfilgrastim + rituximab (up to six-fold when compared to rituximab alone (* p<0,005), and up to four-fold (* p<0,005) when compared to filgrastim + rituximab. C, pictures of spleens of mice treated with rituximab, filgrastim + rituximab or pegfilgrastim + rituximab after four weeks of treatments. 
